blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2621532

EP2621532 - GENERATION, CHARACTERIZATION AND USES THEREOF OF ANTI-HER3 ANTIBODIES [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  18.10.2013
Database last updated on 18.05.2024
Most recent event   Tooltip18.10.2013Withdrawal of applicationpublished on 20.11.2013  [2013/47]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2013/32]
Inventor(s)01 / ZHANG, Ningyan
315 Gentry Lane
Ambler, PA 19002-3613 / US
02 / PRESTA, Leonard G.
301 S. California Avenue
Palo Alto, CA 94304 / US
 [2013/32]
Representative(s)Horgan, James Michael Frederic
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
[N/P]
Former [2013/32]Horgan, James Michael Frederic
Merck & Co., Inc. European Patent Department Hertford Road Hoddesdon
Hertfordshire EN11 9BU / GB
Application number, filing date11829799.327.09.2011
WO2011US53436
Priority number, dateUS20100388157P30.09.2010         Original published format: US 388157 P
[2013/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012044612
Date:05.04.2012
Language:EN
[2012/14]
Type: A1 Application with search report 
No.:EP2621532
Date:07.08.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 05.04.2012 takes the place of the publication of the European patent application.
[2013/32]
Search report(s)International search report - published on:US05.04.2012
ClassificationIPC:A61K39/395
[2013/32]
CPC:
A61P35/00 (EP); C07K16/32 (EP); C07K2317/24 (EP);
C07K2317/92 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/32]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ERZEUGUNG, KENNZEICHNUNG UND VERWENDUNGEN VON ANTI-HER3-ANTIKÖRPERN[2013/32]
English:GENERATION, CHARACTERIZATION AND USES THEREOF OF ANTI-HER3 ANTIBODIES[2013/32]
French:GÉNÉRATION, CARACTÉRISATION ET UTILISATIONS D'ANTICORPS ANTI-HER3[2013/32]
Entry into regional phase02.05.2013National basic fee paid 
02.05.2013Search fee paid 
02.05.2013Designation fee(s) paid 
02.05.2013Examination fee paid 
Examination procedure28.03.2013Amendment by applicant (claims and/or description)
02.05.2013Examination requested  [2013/32]
10.09.2013Despatch of communication that the application is refused, reason: Examination on filing A.90(5) {1}
10.10.2013Application withdrawn by applicant  [2013/47]
Fees paidRenewal fee
30.09.2013Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]US2006183194  (BALLINGER ET AL)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.